SCHEMBL9907283

SCHEMBL9907283

COC(=O)CNC(Cc1ccc(N=O)cc1)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
MIF P14174 1/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FPR2 P25090 1/20 0.40
ATM Q13315 2/20 0.40
TSHR P16473 1/20 0.40
LNPEP Q9UIQ6 1/20 0.40
MDM4 O15151 1/20 0.40
MDM2 Q00987 1/20 0.40
LCK P06239 1/20 0.40
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364896 0.82 ATM (0.57) KMT2AMEN1ATMALDH1A1THRB
SCHEMBL25101017 0.82 FPR2 (0.44) KMT2AMIFESR1ESR2NPSR1
SCHEMBL3266154 0.78 ITGA4 (0.45) KMT2AMEN1ALDH1A1
SCHEMBL3266156 0.78 ITGA4 (0.45) KMT2AMEN1ALDH1A1
SCHEMBL30823314 0.76 PPARG (0.60) KMT2AMEN1ALDH1A1
SCHEMBL27136481 0.76 PPARG (0.60) KMT2AMEN1ALDH1A1
SCHEMBL30866186 0.75 FOLH1 (0.52) KMT2AMEN1ESR1ESR2TSHR
SCHEMBL10092611 0.75 ALDH1A1 (0.48) KMT2AMEN1MIFESR1ESR2
SCHEMBL15147852 0.75 KLK5 (0.55)
SCHEMBL15148245 0.75 KLK5 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120276001-A1 BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS Nordion (Canada) Inc (CA) 2012-11-01 US disclosed
US-8198101-B2 Bifunctional polyazamacrocyclic chelating agents NORDION (CANADA) INC. (CA) 2012-06-12 US disclosed
US-20090202521-A1 Bifunctional Polyazamacrocyclic Chelating Agents MDS (CANADA) INC. (CA) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202521-A1 Bifunctional Polyazamacrocyclic Chelating Agents LPXN, FCGRT, POLQ KMT2A 900/4885MEN1 691/4885MIF 3782/4885
US-20120276001-A1 BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS LPXN, FCGRT, F13A1 KMT2A 999/4885MEN1 497/4885MIF 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.